DAGLα Double Nickase Plasmid (h): sc-402826-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DAGLα Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DAGLα Double Nickase Plasmid (h) and DAGLα Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DAGLA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DAGLα Antibody (E-6): sc-390409
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DAGLα Double Nickase Plasmid (h) | sc-402826-NIC | 20 µg | $410.00 | |||
DAGLα Double Nickase Plasmid (h2) | sc-402826-NIC-2 | 20 µg | $410.00 |
DAGLA encodes diacylglycerol lipase alpha (DAGLα), a membrane-associated serine hydrolase that catalyzes formation of the endocannabinoid 2-arachidonoylglycerol (2-AG) from diacylglycerol. By controlling 2-AG availability, DAGLα regulates cannabinoid receptor signaling and synaptic plasticity, linking phospholipid metabolism to neuromodulatory signaling networks. DAGLα activity interfaces with lipid second-messenger pathways, including PLC-dependent diacylglycerol turnover and downstream eicosanoid/endocannabinoid balance. Dysregulated endocannabinoid signaling and lipid homeostasis involving DAGLA have been investigated in the context of neurodevelopmental and neuropsychiatric phenotypes as well as broader metabolic and inflammatory biology.
DAGLα Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DAGLA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DAGLA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DAGLA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DAGLA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.